.png | CAS_number = 113-59-7 | ATC_prefix = N05 | ATC_suffix = AF03 | ATC_supplemental = | PubChem = 2729 | DrugBank = APRD00718 | chemical_formula = C18H18ClNS | molecular_weight = 315.861 g/mol | bioavailability = incomplete | protein_bound = | metabolism = hepatic | elimination_half-life = 8 to 12 hours | pregnancy_category = Only if clearly needed | legal_status = Rx-Only | routes_of_administration = oral (tablets, syrup, concentrate), intramuscular (seldom) | excretion = feces and urine }} Chlorprothixene is a typical antipsychotic drug of the thioxanthene class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). Its principal indications are the treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occurring as part of bipolar disorders.
The drug was introduced 1959 to the market on a global scale and is hence a first generation antipsychotic with 45+ years of clinical experience. It is still today of clinical and also some research interest.
An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine (intrinsic) analgesic effects. However, Chlorprothixene can be used as comedication in severe chronic pain. Also, like most antipsychotics, chlorprothixene has antiemetic effects.
Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side effects and liver damage seem to appear with an appreciable lower frequency. The elderly are particularly sensitive to anticholinergic side effects of chlorprothixene (precipitation of narrow angle glaucoma, severe obstipation, difficulities in urinating, confusional and delirant states). In patients >60 years the doses should be particularly low.
Early and late extrapyramidal side effects may occur but have been noted with a low frequency (one study with a great number of participants has delivered a total number of only 1%).
On the right table are some guidelines given for daily dosages as follows (dependent on the clinical situation). Some reflect extended clinical experience from decades of usage.
| schizophrenia | 100mg to 200mg |
| exogenic psychosis (e.g. drug psychosis) | 100mg to 200mg |
| acute mania | 45mg to 150mg |
| agitated depressions | 45mg to 150mg |
| alcohol- and drug-withdrawal | 50mg to 150mg |
| non-psychotic agitation and anxiety | 30mg to 150mg |
| acute reactive state to stress/trauma | 30mg to 100mg |
| psychoneurotic states | 30mg to 100mg |
| insomnia | 15mg to 100mg |
| cotreatment of severe chronic pain | 30mg daily initial, increasing to 60 or 90mg (max. 120mg) |
If chlorprothixene is to be withdrawn, it should not be stopped abruptly, but the dose should be decreased steadily.
If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side effects of opioids considerably.
Avoid the concomitant use of chlorprothixene and tramadol (Ultram®). Massive seizures may be encountered with this combination.
Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbiturates. Choose particular low doses of these drugs.
Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
Klorprotixen | Chlorprothixen | Klórprotixén | Хлорпротиксен | Klorprotixen
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Chlorprothixene".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world